Business Context and Reporting Period
Protalix Biotherapeutics, Inc. filed this Form 8-K on February 15, 2012. The company is incorporated in Florida and maintains its principal executive offices in Carmiel, Israel. The filing primarily addresses a planned underwritten public offering of common stock and provides a snapshot of liquidity as of December 31, 2011.
Key Financial Metrics
- Cash and Cash Equivalents: $27,001,000 as of December 31, 2011.
- Revenue, Profit, and Margins: The filing text does not provide a clear value for revenue, profit, or margins for the current or prior periods.
- Debt and Liquidity: Specific debt figures are not disclosed in this report; however, the company holds significant cash reserves.
- Financial Statements: Audited consolidated financial statements are not yet available pending the completion of the offering described in Item 7.01.
Material Changes and Corporate Actions
The primary material event is the announcement of an intended underwritten public offering of common stock, subject to market conditions. Jefferies & Company, Inc. is acting as the sole book-running manager, with Canaccord Genuity Inc. and Oppenheimer & Co. Inc. as co-managers. The company expects to grant underwriters a 30-day option to purchase additional shares to cover over-allotments. There is no assurance regarding the completion, timing, size, or terms of the offering.
Guidance, Risks, and Contingencies
Management has updated the risk factors in its periodic reports in connection with the proposed offering. The filing explicitly states that the offering is subject to market conditions and that there can be no assurance as to whether or when it may be completed. The information regarding the offering and updated risk factors is not deemed "filed" for purposes of Section 18 of the Exchange Act unless expressly incorporated by reference.
Investor Verification Checklist
- Verify the final terms, size, and completion status of the underwritten public offering.
- Review the updated risk factors attached as Exhibit 99.2 for new disclosures related to the offering.
- Monitor the release of audited consolidated financial statements, which are currently unavailable.
- Confirm the utilization of the $27,001,000 cash balance and any potential dilution from the new share issuance.